Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

By afschroeder • August 22, 2025

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton J, Dowdy S, Zhang L, Hallberg D, Velculescu VE, Slamon DJ, Wahner-Hendrickson AE. Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2025 Jul 28;35(10):102028. doi: 10.1016/j.ijgc.2025.102028. Epub ahead of print. PMID: 40839974.

Tags: CDK4/6 inhibitor, Cyclin-Dependent Kinases, Fellow, Hematology/Oncology, ovarian cancer, Palbociclib, Publications, targeted therapy

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]